Journal Highlight: Reconstructing the pipeline by introducing multiplexed MRM-MS for cancer biomarker verification: An NCI-CPTC initiative perspective

Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: An NCI-CPTC initiative perspective

Proteomics - Clinical Applications 2010, 4, 904-914
Henry Rodriguez, Robert Rivers, Christopher Kinsinger, Mehdi Mesri, Tara Hiltke, Amir Rahbar, Emily Boja

Abstract: Proteomics holds great promise in personalized medicine for cancer in the post-genomic era. In the past decade, clinical proteomics has significantly evolved in terms of technology development, optimization and standardization, as well as in advanced bioinformatics data integration and analysis. Great strides have been made for characterizing a large number of proteins qualitatively and quantitatively in a proteome, including the use of sample fractionation, protein microarrays and MS. It is believed that differential proteomic analysis of high-quality clinical biospecimen (tissue and biofluids) can potentially reveal protein/peptide biomarkers responsible for cancer by means of their altered levels of expression and/or PTMs. Multiple reaction monitoring, a multiplexed platform using stable isotope dilution-MS with sensitivity and reproducibility approaching that of traditional ELISAs commonly used in the clinical setting, has emerged as a potentially promising technique for next-generation high-throughput protein biomarker measurements for diagnostics and therapeutics.

• This paper is free to view to separationsNOW registered users until the end of February 2011. After this time it will be available via Wiley's Pay-Per-View service for US$29.95.
• Click here to access the abstract of this paper. From here you can progress to read the full paper.
• Click here for more details on Proteomics - Clinical Applications